MARKET

ABIO

ABIO

ARCA BIOPHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.540
+0.010
+0.28%
Opening 10:29 06/24 EDT
OPEN
3.580
PREV CLOSE
3.530
HIGH
3.580
LOW
3.520
VOLUME
18.13K
TURNOVER
--
52 WEEK HIGH
8.61
52 WEEK LOW
2.920
MARKET CAP
51.01M
P/E (TTM)
-1.8308
1D
5D
1M
3M
1Y
5Y
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting virtual presentations as well as private meetings with qu...
ACCESSWIRE · 1d ago
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11)
Benzinga · 05/12 12:57
BRIEF-Arca Biopharma Announces First Quarter 2021 Financial Results
reuters.com · 05/11 21:01
ARCA biopharma Q1 EPS $(0.33) Up From $(0.83) YoY
ARCA biopharma (NASDAQ:ABIO) reported quarterly losses of $(0.33) per share. This is a 60.24 percent increase over losses of $(0.83) per share from the same period last year.
Benzinga · 05/11 20:41
ARCA biopharma reports Q1 results
ARCA biopharma (ABIO): Q1 GAAP EPS of -$0.33.Cash and cash equivalents of $66.93M.Press Release
Seekingalpha · 05/11 20:31
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2021 financial results and provided a corporate u...
GlobeNewswire · 05/11 20:15
10-Q: ARCA BIOPHARMA, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Management's Discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/11 20:08
-- Earnings Flash (ABIO) ARCA BIOPHARMA Posts Q1 Loss $-0.33
MT Newswires · 05/11 16:26
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABIO. Analyze the recent business situations of ARCA BIOPHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABIO stock price target is 7.00 with a high estimate of 7.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 1.01M
% Owned: 7.03%
Shares Outstanding: 14.41M
TypeInstitutionsShares
Increased
6
265.42K
New
4
54.32K
Decreased
3
8.00K
Sold Out
7
256.26K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.46%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
Chairman/Director
Robert Conway
Chief Executive Officer/President/Director
Michael Bristow
Chief Financial Officer/Chief Accounting Officer
C. Jeffrey Dekker
Chief Operating Officer
Thomas Keuer
Senior Vice President/General Counsel/Secretary
Christopher Ozeroff
Vice President
Christopher Graybill
Lead Director
Linda Grais
Director
Anders Hove
Director
Daniel Mitchell
Director
Raymond Woosley
No Data
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Webull offers kinds of Arca Biopharma Inc stock information, including NASDAQ:ABIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABIO stock methods without spending real money on the virtual paper trading platform.